Please login to the form below

Not currently logged in
Email:
Password:

Partner for Sanofi on pneumonia KB001

KaloBios has announced an agreement with Sanofi Pasteur for the development of KB001 for Pseudomonas aeruginosa (Pa) infections

KaloBios Pharmaceuticals has announced an agreement with Sanofi Pasteur for the development and commercialisation of KB001 for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections.

Sanofi Pasteur (the vaccines division of the sanofi-aventis Group), will be responsible for the development and commercialisation of KB001, an investigational new biologic, and initially focus on hospital indications, including the prevention of Pa pneumonias in mechanically ventilated patients.

KaloBios will focus on developing and commercialising KB001 for use in treating patients with cystic fibrosis and bronchiectasis, an obstructive lung disease aggravated by bacterial infections.

Under the terms of the agreement, KaloBios will receive an upfront payment of $35m from Sanofi Pasteur, plus development, regulatory and commercial milestones for a potential further $255m, as well as royalties on eventual product sales. Sanofi Pasteur also has the option to acquire commercial rights to KaloBios' indications for KB001 outside the US and co-promotion rights in the US.

"Hospital-based pneumonias, especially those associated with mechanically ventilated patients in the ICU, are a life-threatening complication that can significantly increase mortality and morbidity as well as add tens of thousands of dollars to the cost of a hospital stay," said Dr Tillman Pearce, chief medical officer of KaloBios.

"KB001's novel mechanism of action against Pa provides a unique means of fighting these infections, which are often resistant to antibiotic therapies. We also think this novel mechanism could have a significant impact on Pseudomonas aeruginosa infections in cystic fibrosis patients as well."

11th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Eye for Pharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics